Find clinical trials for Chronic Lymphocytic Leukemia in Washington, DC
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Chronic Lymphocytic Leukemia trials near Washington, DC, USA:
zanubrutinib treatment in participants with previously untreated chronic lymphocytic leukemia (CLL). This study is designe...
Phase 2
Baltimore, Maryland, United States and 33 other locations
or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic...
Phase 3
Bethesda, Maryland, United States and 112 other locations
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...
Phase 2
Manassas, Virginia, United States and 73 other locations
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; par...
Phase 3
Bethesda, Maryland, United States and 147 other locations
This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic...
Phase 3
Northwest WA, Wisconsin, United States and 129 other locations
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic ...
Phase 2
Bethesda, Maryland, United States and 133 other locations
objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic...
Phase 3
Washington D.C., District of Columbia, United States and 203 other locations
Epcoritamab will be tested either inRelapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as:* Monotherapy, or* Com...
Phase 1, Phase 2
Bethesda, Maryland, United States of America and 82 other locations
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic...
Phase 3
Fairfax, Virginia, United States and 194 other locations
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL...
Phase 1, Phase 2
Washington D.C., District of Columbia, United States and 83 other locations
Clinical trials
Research sites
Resources
Legal